Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid (Insulin Aspart), NovoMix 30 (Biphasic Insulin Aspart 30 [insulin aspart/insulin protamine aspart]) or Levemir (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart (Primary) ; Insulin detemir (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Novo Nordisk

Most Recent Events

12 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
10 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
04 Dec 2008 Planned number of patients changed from 4300 to 6500.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight